MedTrace Logo

A Study of AL8326 in Non-Small Cell Lung Cancer

NCT06794957 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 158

Last updated 2025-01-27

No results posted yet for this study

Summary

This trial is a multicenter, single arm, open, phase IB clinical trial, designed to evaluate the preliminary efficacy and safety of AL8326 in patients with non-small cell lung cancer (NSCLC) who relapsed or progressed after multi line treatment and failed standard treatment.

Conditions

Interventions

DRUG

AL8326 tablets

10mg/tablet;Oral administration, once daily.

Sponsors & Collaborators

  • Advenchen Laboratories, LLC

    lead INDUSTRY

Principal Investigators

  • Xingya Li · The First Affiliated Hospital of Zhengzhou University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-19
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06794957 on ClinicalTrials.gov